Anika Therapeutics, Inc. 10-Q filing
Filed 2025-07-30 · Report date 2025-06-30 · 2025
Filing metadata
- Accession number
- 0001171843-25-004826
- Form type
- 10-Q
- CIK
- 0000898437
- Primary document
- https://www.sec.gov/Archives/edgar/data/898437/000117184325004826/anik20250630_10q.htm
Extracted primary information
This filing includes deterministic financial metrics extracted from public filing data for Anika Therapeutics, Inc..
Reported financial metrics
| Metric | Current | Prior | Change |
|---|---|---|---|
| Revenue | $54.4M | - | - |
| Cost Of Revenue | $25.3M | - | - |
| Gross Profit | $29.0M | - | - |
| Operating Income | $-8.5M | - | - |
| Net Income | $-8.8M | - | - |
| Eps Basic | -0.62 | - | - |
| Eps Diluted | -0.62 | - | - |
| Cash And Equivalents | $53.2M | - | - |
| Total Assets | $187.7M | - | - |
| Shareholders Equity | $147.7M | - | - |
| Operating Cash Flow | $-319,000 | - | - |
| Capital Expenditures | $4.3M | - | - |